When is a Potent Antibody Against a Good Target Not a Drug? - Adam Drake, Ph.D.

July 22, 2022

When is a potent antibody against a good target not a drug? The case for early PK Presented by Adam Drake, Ph.D. - Director In Vivo Pharmacology, Ichnos Sciences Biotherapeutics, SA, Switzerland Presented on 20 June 2022 in Basel, Switzerland

When is a Potent Antibody Against a Good Target Not a Drug? - Adam Drake, Ph.D.

Potency of PD-1+CTLA-4 BiSpecific or Combination in a Humanized Mouse Model - Richard Stebbings, Ph.D.

Of Mice and Men - FcRn Biology and Its Implications in a Therapeutic Perspective - Jan Terje Andersen, Ph.D.

Preclinical Assessment of Engineered Immunoglobulins in Immune Humanized Mice - Brian Soper, Ph.D.

In Vivo CAR T Cell Generation in Humanized Mouse Models

Of Mice and Men - FcRn Biology and Its Implications in a Therapeutic Perspective - Torleif Tollesfrud Gjølberg, Ph.D.

Cytokine Release in the Context of T Cell Bispecific Antibody (TCB) Therapies - Gabrielle Leclerq, Ph.D.